Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;49(6):381-386.
doi: 10.5152/tud.2023.23150.

One-year Follow-up Results of Transperineal Biopsy For Patients Undergoing Irreversible Electroporation Treatment in Localized Prostate Cancer

Şükrü Ali Altan  1 , Pınar Güleryüz Kızıl  2 , Nefise Çağla Tarhan  3 , Oztug Adsan  1
Affiliations

One-year Follow-up Results of Transperineal Biopsy For Patients Undergoing Irreversible Electroporation Treatment in Localized Prostate Cancer

Şükrü Ali Altan et al. Urol Res Pract. 2023 Nov.

Abstract

Objective: This article reports on the early results of a 1-year follow-up study investigating the efficacy of irreversible electroporation in the treatment of localized prostate cancer.

Methods: The study included 18 out of 40 patients diagnosed with low- and intermediate-risk prostate cancer who underwent irreversible electroporation. Treatment results were evaluated through confirmation biopsies, comparing prostate-specific antigen levels, international prostate symptom scoring, and international index of erectile dysfunction scores before irreversible electroporation and at the 12-month mark.

Results: The mean age of the patients was 61.1 years (SD ±6.5). Out of the 18 patients, 16 were tumor free (88.8%), while 2 experienced recurrences, one within the treatment field and the other outside of it (P < .001). Irreversible electroporation significantly reduced mean prostate-specific antigen levels (6.73 ng/mL vs. 2.05 ng/mL, P < .001), indicating a 69.5% reduction within 12 months. Furthermore, there was a significant improvement in mean international prostate symptom scores at the 12-month followup (10.05 vs. 7.52, P=.003). The mean international index of erectile dysfunction scores before treatment was 19.17 (SD ±5.85), and after irreversible electroporation, it was 18.67 (SD ±6.34), with no statistically significant change (P=.065).

Conclusion: The short-term oncological results of irreversible electroporation treatment are promising, particularly for patients in the low- and intermediate-risk groups. Additionally, irreversible electroporation does not negatively impact the international index of erectile dysfunction; however, it may lead to a decrease in international prostate symptom scores.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Three-dimensional view of targeted transperineal fusion biopsy areas.
Figure 2.
Figure 2.
Schematic and real-time application of irreversible electroporation needles.
See this image and copyright information in PMC

References

    1. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localised prostate cancer. N Engl J Med. 2016;375(15):1415 1424. (10.1056/NEJMoa1606220) - DOI - PubMed
    1. Lodeizen O, de Bruin M, Eggener S,et al. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019;37(3):409 418. (10.1007/s00345-018-2364-x) - DOI - PMC - PubMed
    1. Guo RQ, Guo XX, Li YM, Bie ZX, Li B, Li XG. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021;26(3):461 484. (10.1007/s10147-020-01847-y) - DOI - PubMed
    1. Rubinsky L, Guenther E, Mikus P, Stehling M, Rubinsky B. Electrolytic effects during tissue ablation by electroporation. Technol Cancer Res Treat. 2016;15(5):NP95 NP103. (10.1177/1533034615601549) - DOI - PubMed
    1. Blazevski A, Scheltema MJ, Amin A, Thompson JE, Lawrentschuk N, Stricker PD. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. 2020;125(3):369 378. (10.1111/bju.14951) - DOI - PubMed

LinkOut - more resources